The patent provides protection for “multiple techniques” for delivering the stem cells to treat the conditions, which also include congestive heart failure and myocardial ischemia, according to a statement from Cleveland-based Athersys.
The patent applies to Athersys’ MultiStem technology, an off-the-shelf stem cell treatment derived from the bone marrow of adults or other nonembryonic sources. The technology has shown promise in reducing inflammation, protecting damaged tissue and forming new blood vessels.
“Cardiovascular disease represents an important opportunity area for MultiStem therapy, and [this] patent provides the company with additional protection for its product candidates in this high value area,” COO B.J. Lehmann said.
In August, Athersys said it would soon begin a phase 2 trial with heart attack patients.
In addition to cardiovascular conditions, Athersys’ MultiStem is also being investigated for the treatment of inflammatory bowel disease, stroke and blood diseases.
About two months ago, Athersys closed a stock purchase deal with Aspire Capital Fund that could be worth up to $20 million.